Cargando…
PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
Autores principales: | Zurko, Joanna, Chaney, Katherine, Astle, John M., Johnson, Bryon D., Hari, Parameswaran, Shah, Nirav N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485669/ https://www.ncbi.nlm.nih.gov/pubmed/33853295 http://dx.doi.org/10.3324/haematol.2021.278461 |
Ejemplares similares
-
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
por: Knight, Jennifer M., et al.
Publicado: (2022) -
Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes
por: Knight, Jennifer M., et al.
Publicado: (2022) -
P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023) -
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019) -
Gut microbiome and CAR-T therapy
por: Abid, Muhammad Bilal, et al.
Publicado: (2019)